CAFC must end ‘existential threat’ to patents, argues Sequenom

Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Sequenom’s en banc petition rejected by Federal Circuit

2 December 2015 The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc.

Americas

Eyes on Supreme Court after Sequenom rejection

3 December 2015 There were no surprises, but plenty of alarms yesterday following the US Court of Appeals for the Federal Circuit’s decision to reject Sequenom’s request for a re-hearing of its dispute with Ariosa Diagnostics en banc.

Americas

Sequenom petitions SCOTUS over Ariosa row

22 March 2016 Sequenom has urged the US Supreme Court to hear its patent dispute with Ariosa Diagnostics.

More on this story

Americas

Sequenom’s en banc petition rejected by Federal Circuit

2 December 2015 The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc.

Americas

Eyes on Supreme Court after Sequenom rejection

Americas

Sequenom petitions SCOTUS over Ariosa row

22 March 2016 Sequenom has urged the US Supreme Court to hear its patent dispute with Ariosa Diagnostics.

More on this story

Americas

Sequenom’s en banc petition rejected by Federal Circuit

2 December 2015 The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc.

Americas

Eyes on Supreme Court after Sequenom rejection

Americas

Sequenom petitions SCOTUS over Ariosa row

22 March 2016 Sequenom has urged the US Supreme Court to hear its patent dispute with Ariosa Diagnostics.